Breaking News, Collaborations & Alliances

Capsida Biotherapeutics, Prevail Therapeutics Enter Strategic R&D Alliance

Leverages Capsida's AAV engineering platform to advance clinically translatable capsids paired with Prevail's cargo to develop gene therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Capsida Biotherapeutics Inc. has entered a multi-year strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Co., to develop genetic medicines for serious diseases. Prevail will leverage Capsida’s novel adeno-associated virus (AAV) engineering platform to identify and advance clinically translatable capsids paired with Prevail’s cargo to develop best-in-class, IV-administered gene therapies directed to specified targets known to cause serious di...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters